Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and considered life-saving.

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.